CooperVision’s MyDays Energys contact lenses hit US market
First 1-Day Lens that combines DigitalBoost and Aquaform technologies
designed to deliver comfort for ‘always on’ digital lifestyles
IKA Keratoconus Symposium 2023: Live patient Q&A, in-person white paper development, and more
Andrew Morgenstern, OD, FAAO, FNAP, sits down to discuss the inaugural IKA Keratoconus Symposium in Scottsdale, Arizona, in April 2023.
Orasis Pharmaceuticals’ NDA for CSF-1 for presbyopia accepted by FDA
A PDUFA goal date of October 22, 2023 was assigned to the investigational eye drop candidate for the treatment of presbyopia.
Pegcetacoplan approved by FDA for the treatment of geographic atrophy
Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.
Harrow, ImprimisRx launch compounded atropine formulation
The next-generation compound of atropine does not contain preservatives or boric acid and can be stored at room temperature for up to 180 days.
Rigid gas permeable contact lens deposition measured via radiolabeled proteins
The Biosciences group of the Centre for Ocular Research and Education (CORE) determined protein deposits on rigid gas permeable contact lens via radioactive counts by using a radiolabeled lysozyme in an artificial tear solution.
Digging into the 6-month first-in-human clinical trial data from SpyGlass Pharma
Patrick Mooney, CEO of SpyGlass Pharma, sits down to discuss the 6-month first-in-human clinical trial data of their drug delivery platform with bimatoprost, which is implanted during routine cataract surgery.
Ocuphire announced FDA acceptance of NDA for Nyxol for the reversal of mydriasis, sets PDUFA date
Phentolamine ophthalmic solution 0.75%, or Nyxol, receives a PDUFA date of September 28, 2023, for the indication of reversal of pharmacologically induced mydrasis.
FDA approves EYLEA for treatment of retinopathy of prematurity
Aflibercept, a VEGF inhibitor previously indicated for a variety of retinal diseases, is the first pharmacological treatment for retinopathy of prematurity in preterm infants.
Dompe's past developments, continual progress in NGF applications
Flavio Mantelli, MD, PhD, Chief Medical Officer at Dompé, shares about the company's role in nerve growth factor (NGF) applications in ophthalmic disease and other human indications.
6-month data from first-in-human trials shows promise for bimatoprost-eluting IOL
SpyGlass Pharma presented new data at the Glaucoma 360 New Horizons Forum that supports the use of their proprietary drug delivery platform to lower IOP in patients with glaucoma or ocular hypertension.
International Keratoconus Academy Symposium: What to expect
CEO and cofounder of the International Keratoconus Academy S. Barry Eiden, OD, FAAO, FSLS, sits down to discuss the inaugural symposium, which will be held April 22-23, 2023, in Scottsdale, Arizona.
IDOC drives ethical frame buying behavior with 10 for 10 annual rebate
All new and existing IDOC inventory management accounts will receive an additional annual benefit as part of their initiative to increase optical profitability in independent practices.
FDA approves ML6710i photodynamic laser for use with VISUDYNE
Bausch + Lomb and Modulight announce the photodynamic laser for use with photodynamic therapy was approved by the FDA for the treatment of patients with subfoveal choroidal neovascularization due to AMD.
CDC calls for discontinued use of EzriCare artificial tears amidst infection investigation
A wave of infections across 11 states have been linked to artificial tear use, leading to permanent vision loss, hospitalization, and one death.
IDOC and Three Rivers Optical announce merger
Two leaders in optometry are coming together to expand their suite of services for independent practices.
Glaukos announces updates to corneal pipeline programs
Two novel, dropless technologies for keratoconus and dry eye disease make major advances with more to come later in 2023.
First patient enrolled in Ocuphire Phase 3 pivotal trial of Nyxol for presbyopia
The VEGA-2 pivotal trial is investigating Nyxol alone and Nyxol with adjunctive low-dose pilocarpine therapy for the treatment of presbyopia.
Shamir releases Glacier PLUS™ Metaform™ coating on Transitions™ Signature® GEN 8 Brown and Grey
The patented AR lens coating creates thinner, stronger lenses than the alternative, and is now available to patients who love Transitions lenses.
Zeiss Vision unveils ClearView Single Vision lenses
The lens giant pairs precision vision of freeform-optimized lenses with the cost benefit of standard single vision lenses.
Harrow enters agreement to acquire exclusive US rights to suite of Novartis products
In the second deal between Harrow and Novartis, the former is expected to add 5 ophthalmic products to its portfolio.
EyeCon 2022: Ensuring your patients receive thorough presbyopic care
Marc R. Bloomenstein, OD, FAAO, shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."
Creating an inclusive and equitable workspace
Ruth Shoge, OD, MPH, FAAO, shares key takeaways from her EyeCon 2022 presentation, "Diversity in practice, creating an inclusive and equitable workspace."
2022 brought pipeline advances in glaucoma, retina, cornea, and beyond
Justin Schweitzer, OD, gives a brief overview of his EyeCon 2022 presentations, reflecting on pipeline advancements made in optometry in 2022.
EyeCon 2022: Improve your practice with these industry innovations
Adam Ramsey, OD, shares key takeaways from his EyeCon 2022 presentation, "Advances in industry innovations to improve your practice."
EyeCon 2022: Advances in presbyopia
Mile Brujic, OD, FAAO, shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."
EyeCon 2022: The past, present, and future of contact lens technology
Lyndon Jones, BSc, PhD, DSc, FCAHS, FCOptom, DipCLP, DipOrth, FAAO, FIACLE, FBCLA , shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."
FDA approves latanoprost ophthalmic solution from Thea for reduction of IOP
As the first and only preservative-free formulation of latanoprost, IYUZEH 0.005% is approved to reduce IOP in patients with open-angle glaucoma or ocular hypertension.
EyeCon 2022: Diversity, equity, and inclusion in your optometry practice
Adam Ramsey, OD, shares key takeaways from his presentation on diversity, equity, and inclusion in you optometry practice, which he presented during EyeCon 2022.
FDA grants 510(k) clearance to Bausch + Lomb for Biotrue® Hydration Boost contact lens rehydrating drops
The preservative-free, multi-dose contact lens rehydrating drops are expected to hit the market in early 2023.
2 Clarke Drive Cranbury, NJ 08512